FormWeb • lamiVUDine-zidovudine

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Add Formweb to your mobile device

Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

lamiVUDine-zidovudine

lamiVUDine-zidovudine

Non-formulary AIDS Drugs Formulary
Therapeutic Interchange

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Combivir	TABLET, ORAL	150 mg-300 mg

Comments:

Ordered Formulation

Therapeutic Interchange

lamiVUDine-zidovudine (Combivir)

150 mg-300 mg tablet oral

lamiVUDine (Epivir) AND zidovudine (AZT, Retrovir)

ONE 150 mg lamiVUDine tablet PLUS ONE 300 mg zidovudine tablet

Last updated: Jun. 29, 2022

Black Box Warning: lamiVUDine: Lactic acidosis, hepatomegaly; exacerbations of hepatitis b; dosing formulation
Black Box Warning: Zidovudine: Hematological adverse events; myopathy; lactic acidosis; hepatomegaly
HAZ-MED: Group 2 (zidovudine)

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.